Skip to main content

Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10522-CV

Sf21 Insect Cell Expressed
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
10522-CV-01M
10522-CV-100

Key Product Details

Source

Sf 21 (baculovirus)

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived sars-cov-2 Spike S1 Subunit protein
Val16-Pro681, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.30 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Val16, sequence confirmed by mass spectrometry

Predicted Molecular Mass

75 kDa

SDS-PAGE

78-92 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag ( (Catalog # 933-ZN).

Scientific Data Images for Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein, CF

Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein Bioactivity

Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein Bioactivity

Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein (10522-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.
Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein SDS-PAGE

Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein SDS-PAGE

2 μg/lane of Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein (10522-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 78-92 kDa and 70-80 kDa, respectively.

Detection of SARS-CoV-2 Spike S1 Protein bound to ACE-2 expressing cells by flow cytometry.

In a functional flow cytometry test, (A) Recombinant SARS-CoV-2 Spike S1 subunit His-tag Protein (Catalog # 10522-CV) binds to HEK293 human embryonic kidney cell line transfected with recombinant human ACE-2 and EGFP. Ligand binding was detected by staining cells with APC-conjugated anti-His Monoclonal Antibody (IC050A), which does not stain the cells in the absence of recombinant protein (B).

Formulation, Preparation and Storage

10522-CV
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 200 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Spike S1 Subunit

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). Based on structural biology studies, the receptor binding domain (RBD), located in the C-terminal region of S1, can be oriented either in the up/standing or down/lying state (6). The standing state is associated with higher pathogenicity and both SARS-CoV-1 and MERS can access this state due to the flexibility in their respective RBDs. A similar two-state structure and flexibility is found in the SARS-CoV-2 RBD (7). Based on amino acid (aa) sequence homology, the SARS-CoV-2  S1 subunit has 65% identity with SARS-CoV-1 S1 subunit,  but only 22% homology with the MERS S1 subunit. The low aa sequence homology is consistent with the finding that SARS and MERS bind different cellular receptors (8). The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE2), but with much higher affinity and faster binding kinetics (9). Before binding to the ACE2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains in the trimeric structure is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy (10). Polyclonal antibodies to the RBD of the SARS-CoV-2 S1 subunit have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (11). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 virus (12). Lastly, it has been demonstrated the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (13, 14).

References

  1. Wu, F. et al. (2020) Nature 579:265.
  2. Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93.
  3. Bosch, B.J. et al. (2003) J. Virol. 77:8801.
  4. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
  5. Millet, J.K. and G. R. Whittaker (2015) Virus Res. 202:120.
  6. Yuan, Y. et al. (2017) Nat. Commun. 8:15092.
  7. Walls, A.C. et al. (2010) Cell 180:281.
  8. Jiang, S. et al. (2020) Trends. Immunol. https://doi.org/10.1016/j.it.2020.03.007.
  9. Ortega, J.T. et al. (2020) EXCLI J. 19:410.
  10. Wrapp, D. et al. (2020) Science 367:1260.
  11. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007.
  12. Okba, N. M. A. et al. (2020). Emerg. Infect. Dis. https://doi.org/10.3201/eid2607.200841.
  13. Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9.
  14. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.

Long Name

Spike Protein, S1 Subunit

Alternate Names

SARS-CoV-2

UniProt

Additional Spike S1 Subunit Products

Product Documents for Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant SARS-CoV-2 Spike S1 Subunit His-tag Protein, CF

For research use only

Loading...
Loading...
Loading...